Recombinant Destabilase from
Research article published in Current issues in molecular biology (2021)
Abstract
Leeches are amazing animals that can be classified as conditionally poisonous animals since the salivary cocktail they produce is injected directly into the victim, and its components have strictly defined biological purposes, such as preventing blood clot formation. Thrombolytic drugs are mainly aimed at treating newly formed blood clots. Aged clots are stabilized by a large number of isopeptide bonds that prevent the action of thrombolytics. These bonds are destroyed by destabilase, an enzyme of the leech's salivary glands. Here, we conducted a pilot study to evaluate the feasibility and effectiveness of the use of destabilase in relation to blood clots formed during real pathological processes. We evaluated the isopeptidase activity of destabilase during the formation of a stabilized fibrin clot. We showed that destabilase does not affect the internal and external coagulation cascades. We calculated the dose-response curve and tested the ability of destabilase to destroy isopeptide bonds in natural blood clots. The effect of aged and fresh clots dissolving ability after treatment with destabilase coincided with the morphological characteristics of clots during surgery. Thus, recombinant destabilase can be considered as a potential drug for the treatment of aged clots, which are difficult to treat with known thrombolytics.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Leeches are amazing animals that can be classified as conditionally poisonous animals since the salivary cocktail they produce is injected directly into the victim, and its components have strictly defined biological purposes, such as preventing blood clot formation.
Por qué esto importa para la hirudoterapia
Este estudio piloto examinó la destabilase recombinante, una enzima de las glándulas salivales de las sanguijuelas que escinde los enlaces isopeptídicos que estabilizan los coágulos sanguíneos antiguos, los cuales resisten a los trombolíticos convencionales. Los investigadores evaluaron su actividad isopeptidasa durante la formación de coágulos de fibrina estabilizados, establecieron que no afecta las cascadas de coagulación interna ni externa, determinaron una relación dosis-respuesta y demostraron su capacidad para disolver tanto coágulos sanguíneos naturales frescos como antiguos, con observaciones correspondientes a la morfología quirúrgica del coágulo. Este trabajo es directamente relevante para la hirudoterapia y el secretoma salival de la sanguijuela, ya que caracteriza mecanísticamente una enzima específica derivada de la sanguijuela con una acción fibrinolítica distinta de las terapias existentes. Sin embargo, el resumen describe solo un estudio piloto de factibilidad con datos limitados de resultados cuantitativos reportados, y el potencial terapéutico sugerido para los coágulos antiguos requiere una validación adicional sustancial antes de que se pueda considerar cualquier aplicación clínica.
Citación
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: March 18, 2026 · Última actualización del sitio: June 18, 2026